Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06236802 · ClinicalTrials.gov registry record · NA
ProVIDE II Bridging Study
A NA study of BPH With Symptomatic Lower Urinary Tract Symptoms, sponsored by ProVerum Medical.
- Active
- Registry status
- NA
- Development phase
- 40
- Enrollment target
- 8
- Study locations
NCT06236802: Active NA study of BPH With Symptomatic Lower Urinary Tract Symptoms, sponsored by ProVerum Medical.
NCT06236802 is a NA study of BPH With Symptomatic Lower Urinary Tract Symptoms that is active but no longer recruiting, run by ProVerum Medical. The registered enrollment target is 40 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). The trial reports 8 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06236802, a NA study of BPH With Symptomatic Lower Urinary Tract Symptoms, is active but no longer recruiting, sponsored by ProVerum Medical.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of the ProVIDE II Bridging Study is to evaluate the performance of the Generation II delivery system when deploying the ProVee expander in subjects with symptomatic urinary obstruction secondary to BPH.
Primary Outcome
Rate of device or procedure related serious adverse events through 3-months.
Conditions Studied
Interventions
- DEVICE ProVee device
Study Locations (8)
Texas
- Midtown Urology Assoc. PA - Austin
- Urology Austin - Austin
- Houston Methodist Research Institute - Houston
Florida
- Florida Urology Partners, LLP - Tampa
- Avant Concierge Urology - Winter Garden
Illinois
- Comprehensive Urologic Care - Lake Barrington
Nevada
- Sheldon Freeman MD LTD - Las Vegas
Other
- St James Hospital - Dublin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2024-03-06 |
| Est. Completion | 2029-06-01 |
| Phase | NA |
What the registry record for NCT06236802 still lists
NCT06236802 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 1 condition, with BPH With Symptomatic Lower Urinary Tract Symptoms appearing as the primary indexed condition, and to 1 intervention - of which ProVee device is the first listed.
NCT06236802 lists 8 locations in 5 states (Texas, Florida, Illinois).
Frequently Asked Questions
What is clinical trial NCT06236802 about?
NCT06236802 is a clinical study titled "ProVIDE II Bridging Study". The purpose of the ProVIDE II Bridging Study is to evaluate the performance of the Generation II delivery system when deploying the ProVee expander in subjects with symptomatic urinary obstruction secondary to BPH.
What is the current status of trial NCT06236802?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2024-03-06. Estimated completion is 2029-06-01.
What conditions does trial NCT06236802 study?
This clinical trial studies the following conditions: BPH With Symptomatic Lower Urinary Tract Symptoms.
What interventions are being tested in trial NCT06236802?
The interventions under investigation include: ProVee device (DEVICE).
Who is sponsoring clinical trial NCT06236802?
This trial is sponsored by ProVerum Medical, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06236802 being conducted?
This trial has 8 study locations across Florida, Illinois, Nevada, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for BPH With Symptomatic Lower Urinary Tract Symptoms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06236802's enrollment target sits among peer trials
40 1447th of 2000 higher than 465 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI